Lidokain Viatris

Lidocaine, the active ingredient in Lidokain Viatris, is a local anesthetic presented as an injectable solution for intravenous use. It provides local anesthesia for minor surgical procedures, assists in the management of ventricular arrhythmias, and offers pain relief in appropriate clinical settings across the EU market.

GNH USA supplies Lidokain Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine is a local anesthetic that works by blocking nerve conduction in various clinical situations.

Minor surgical procedures: provides local anesthesia to facilitate painless incision and manipulation. Ventricular arrhythmias: stabilizes cardiac electrical activity to prevent abnormal rhythms. Pain relief: reduces pain sensation in targeted tissues during procedures.

Adverse reactions may occur following administration of lidocaine injectable solution.

Common Side Effects: - Tingling or numbness at the injection site - Mild dizziness or light‑headedness - Metallic taste in the mouth - Nausea or mild vomiting - Transient hypotension - Localised swelling or erythema

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmias, including ventricular tachycardia - Central nervous system toxicity such as seizures - Methemoglobinemia - Respiratory depression - Persistent hypotension requiring intervention

Before using lidocaine injectable solution, clinicians should consider several safety measures.

Assess allergy: verify no known hypersensitivity to amide‑type local anesthetics. Monitor cardiac status: observe for signs of arrhythmia, especially in patients with pre‑existing heart disease. Check plasma levels: avoid excessive dosing that could lead to toxicity. Use caution in hepatic impairment: reduced metabolism may increase systemic exposure. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lidocaine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise systemic exposure. - Beta‑blockers (e.g., propranolol): may enhance cardiac depressant effects.

Moderate Interactions (Monitor Closely): - Class III antiarrhythmics (e.g., amiodarone): may require dose adjustment. - Diuretics (e.g., furosemide): can alter protein binding and affect levels. - Other local anesthetics: concurrent use may increase risk of toxicity.